Biocomposites wins two Queen’s Awards for Enterprise in Innovation and International Trade

Why Biocomposites?

Deep expertise and singular focus on
calcium compound medical devices.

Bringing calcium to life®

At Biocomposites, we are pioneering calcium compound devices to regenerate bone and carry antibiotics in bone and soft tissue. With over 30 years’ experience of manipulating the surface chemistry and crystalline properties of calcium compounds, we engineer and manufacture products at the forefront of calcium technology.

Our innovative calcium compound devices range from bone grafts to antibiotic carriers for use in bone and soft tissue. Possessing unique characteristics for regenerating bone and managing infected sites, our products are opening new possibilities for surgeons around the world.

Our products are tried and trusted around the world to change lives. We believe that much of our success, in over 40 countries worldwide, is due to the confidence our surgeons have in our quality control – enabling us to create products of unrivaled quality and performance.

The Queen’s Awards for Enterprise

Biocomposites has been honoured with two awards recognising our excellence in Innovation and International Trade.  Announced annually by Her Majesty The Queen, the awards recognise outstanding achievement by UK businesses.


“Biocomposites identified a significant need to reduce the infection rates from hip and knee replacement surgery. In response they developed STIMULAN Rapid Cure, the first and only calcium sulfate antibiotic carrier that is approved for use in infected bone and soft tissue. The beads in the product deliver an increased level of antibiotics direct to the site of infection and because they absorb as the antibiotic elutes there is no need for further follow-up procedures for the patient.”

International Trade

“Biocomposites’ products are used in over 120,000 procedures every year and is the only supplier providing calcium sulfate antibiotic carriers for use in bone and soft tissue to the NHS. Overseas sales grew by over 200% in a six-year period from 40 countries including the United States, the Netherlands, China, Canada and India.”

Singular focus

With a singular focus on developing innovative calcium compound medical devices, Biocomposites has gained a deep expertise in musculoskeletal infections, trauma, spine, foot and ankle, and sports injuries. Connected with universities and hospitals around the world, Biocomposites continues to innovate in infection management to support surgeons and their patients.

Proprietary technology

We pride ourselves on our power to innovate. This focus and ongoing investment in proprietary technologies has driven our teams to push the frontiers of calcium compound medical devices at every stage – with over 100 grants and registrations of IP, a strong R&D pipeline, and a string of world firsts.

Dedicated to quality

We understand the importance confidence plays in selecting surgical devices. This is why we underpin all our product development with a dedication to quality. Quality people, processes and safeguards that meet and exceed medical standards, right through manufacturing, processing, testing and distribution. All handled in-house to ensure reliable, predictable and reproducible clinical performance.

Hear what surgeons have to say about Biocomposites
Hear what surgeons have to say about Biocomposites

Contact Us

The Biocomposites story

  • 1997 – Management buyout of a ceramics company. Incorporation of Biocomposites Ltd.
  • 1998 – Launch of Bilok and STIMULAN Pellets
  • 1999 – Launch of FORTOSS and Allogran-R
  • 2000 – Incorporation of Biocomposites Inc., Wilmington, NC, USA
  • 2001 – Launch of STIMULAN Kit and Biosteon
  • 2002 – Launch of genex
  • 2003 – Incorporation of Biocomposites (Shanghai) Ltd., Shanghai, China
  • 2004 – Relocation to custom-built headquarters, Keele, Staffordshire, UK
  • 2007 – Launch of genex putty
  • 2009 – Launch of genex ds
  • 2010 – Presence established in India
  • 2011 – Launch of STIMULAN Rapid Cure
  • 2014 – Presence established in Canada
  • 2017 – Launch of STIMULAN Bullet Mat and Introducer
  • 2019 – Launch of genex BGS
  • 2020 – New CE mark for STIMULAN – antibiotic carrier in bone and soft tissue.  Launch of STIMULAN Rapid Cure 3cc. Incorporation of Biocomposites India Pvt. Ltd.
  • 2021 – STIMULAN approved in Canada to treat bacterial infection
  • 2022 – Acquisition of Subiton and SYNIMED
  • 2023 – Acquisition of Artoss GmbH. Investment in Renovos Biologics
  • 2024 – STIMULAN V G phase II clinical trial to treat diabetic foot osteomyelitis commenced.  Incorporation of Biocomposites S.R.L., Prato, Italy